Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Unternehmen & Branche
| Name | TG THERAPEUTICS, INC. |
|---|---|
| Ticker | TGTX |
| CIK | 0001001316 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,36 Mrd. USD |
| Beta | 1,76 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 616,287,000 | 447,179,000 | 2.77 | 1,063,253,000 | 648,020,000 |
| 2025-09-30 | 10-Q | 161,709,000 | 390,895,000 | 2.43 | 1,025,024,000 | 607,218,000 |
| 2025-06-30 | 10-Q | 141,148,000 | 28,187,000 | 0.17 | 702,613,000 | 276,432,000 |
| 2025-03-31 | 10-Q | 120,856,000 | 5,060,000 | 0.03 | 656,689,000 | 237,289,000 |
| 2024-12-31 | 10-K | 329,004,000 | 23,383,000 | 0.15 | 577,690,000 | 222,364,000 |
| 2024-09-30 | 10-Q | 83,879,000 | 3,880,000 | 0.02 | 586,014,000 | 192,157,000 |
| 2024-06-30 | 10-Q | 73,466,000 | 6,879,000 | 0.04 | 401,207,000 | 177,568,000 |
| 2024-03-31 | 10-Q | 63,474,000 | -10,707,000 | -0.07 | 373,323,000 | 160,109,000 |
| 2023-12-31 | 10-K | 233,662,000 | 12,672,000 | 0.09 | 329,587,000 | 160,502,000 |
| 2023-09-30 | 10-Q | 165,815,000 | 113,930,000 | 0.73 | 331,067,000 | 164,769,000 |
| 2023-06-30 | 10-Q | 16,074,000 | -47,610,000 | -0.34 | 220,854,000 | 40,453,000 |
| 2023-03-31 | 10-Q | 7,803,000 | -39,232,000 | -0.28 | 197,358,000 | 27,433,000 |
| 2022-12-31 | 10-K | 2,785,000 | -223,812,000 | -1.65 | 193,572,000 | 58,587,000 |
| 2022-09-30 | 10-Q | 94,000 | -35,818,000 | -0.26 | 217,891,000 | 100,481,000 |
| 2022-06-30 | 10-Q | 594,000 | -40,510,000 | -0.30 | 251,666,000 | 129,035,000 |
| 2022-03-31 | 10-Q | 2,016,000 | -69,013,000 | -0.51 | 303,028,000 | 170,386,000 |
| 2021-12-31 | 10-K | 6,689,000 | -348,101,000 | -2.63 | 379,629,000 | 237,153,000 |
| 2021-09-30 | 10-Q | 2,030,000 | -0.65 | 409,687,000 | ||
| 2021-06-30 | 10-Q | 1,545,000 | -0.59 | 481,400,000 | ||
| 2021-03-31 | 10-Q | 793,000 | -0.69 | 548,699,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.